• 1
    Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 2003; 4: 23756.
  • 2
    Van Laethem J-L, Marechal R. Emerging drugs for the treatment of pancreatic cancer. Expert Opin Emerg Drugs 2007; 12 (2): 30111.
  • 3
    Luger K, Mäder AW, Richmond RK et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 3889: 25160.
  • 4
    Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693705.
  • 5
    Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15: 394757.
  • 6
    Nakagawa M, Oda Y, Eguchi T et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 76974.
  • 7
    Sasaki H, Moriyama S, Nakashima Y et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004; 46: 1718.
  • 8
    Miyake K, Yoshizumi T, Imura S et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008; 36: e19.
  • 9
    Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 76984.
  • 10
    Burgess A, Ruefli A, Beamish H et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693701.
  • 11
    Xu J, Zhou JY, Wei WZ et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008; 68: 671826.
  • 12
    Arnold NB, Arkus N, Gunn J et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007; 13: 1826.
  • 13
    Garcia-Manero G, Assouline S, Cortes J et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; 112: 9819.
  • 14
    Siu LL, Pili R, Duran I et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26: 19407.
  • 15
    Hurwitz H, Nelson B, O’Dwyer PJ et al. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. 2008 ASCO Annual Meeting Proceedings.
  • 16
    Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 2005; 24: 42539.
  • 17
    Danen EH, Yamada KM. Fibronectin, integrins and growth control. J Cell Physiol 2001; 189: 113.
  • 18
    Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008; 76: 135264.
  • 19
    Anderson SN, Towne DL, Burns DJ et al. A high-throughput soft agar assay for identification of anticancer compound. J Biomol Screen 2007; 12: 93845.
  • 20
    Donadelli M, Constanzo C, Beghelli S et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773: 1095106.
  • 21
    Piacentini P, Donadelli M, Costanzo C et al. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006; 448: 797804.
  • 22
    Fournel M, Bonfils C, Hou Y et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7: 75968.
  • 23
    Bonfils C, Kalita A, Dubay M et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008; 14: 34419.
  • 24
    Zhou N, Moradei O, Raeppel S et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008; 51: 40725.
  • 25
    Raeppel S, Zhou N, Gaudette F et al. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103). Bioorg Med Chem Lett 2009; 19: 6449.
  • 26
    Blum KA, Advani A, Fernandez L et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009; 147: 50714.
  • 27
    Bociek RG, Kuruvilla J, Pro B et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). 2008 ASCO Annual Meeting Proceedings.
  • 28
    Crump M, Andreadis C, Assouline S et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. 2008 ASCO Annual Meeting Proceedings.
  • 29
    Galmarini CM, Clarke ML, Falette N et al. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97: 43945.
  • 30
    Clarke ML, Mackey JR, Baldwin SA et al. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res 2002; 112: 2747.
  • 31
    Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 13406.
  • 32
    Goan YG, Zhou B, Hu E et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999; 59: 42047.
  • 33
    Huang L, Sowa Y, Sakai T et al. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2002; 19: 57129.
  • 34
    Donadelli M, Costanzo C, Faggioli L et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003; 38: 5969.
  • 35
    Tolis C, Peters GJ, Ferreira CG et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35: 796807.
  • 36
    Ahmed W, Rahmani M, Dent P et al. The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Cell Cycle 2004; 3: 130511.
  • 37
    Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010; 22: 100312.
  • 38
    Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 40014.